Skip to content
Find a Provider
Christine M. Hay, M.D.

Christine M. Hay, M.D.

she/her/hers

Liver Transplant , Infectious Disease , Surgery

No ratings currently available, see text in Ratings section below for explanation.

UR Medicine Faculty The University of Rochester Medical Faculty Group (URMFG) consists of over 900 specialist and primary care providers spanning 19 departments. URMFG is certified by the National Committee for Quality Assurance.
Accountable Health Partner Accountable Health Partners (AHP) is a network of over 2,000 community and UR medical faculty and a dozen leading hospitals throughout the region. AHP offers a full range of care.
Accepting New Patients

Contact

Appointment (585) 275-0526
Fax (585) 340-4020

About Me

Certified Specialties

Infectious Disease - American Board of Internal Medicine

Faculty Appointments

Professor - Department of Medicine, Infectious Diseases (SMD)

Associate Dean for Admissions - Offices of Medical Education (SMD)

Credentials

Residency & Fellowship

Fellowship, Infectious Disease, Massachusetts General Hospital. 1995 - 1998

Residency, Internal Medicine, Massachusetts General Hospital. 1993 - 1995

Internship, Internal Medicine, Massachusetts General Hospital. 1992 - 1993

Education

MD | Washington University School of Medicine. 1992

Awards

Maxwell Finland Young Investigator's Award, Massachusetts Infectious Disease Society 1999

Kirk Award in Medicine 1992

Alpha Omega Alpha 1991

Brookings Medical School Award 1991

Distinguished Student Scholarship, Washington University School of Medicine 1988 - 1992

Publications

Journal Articles

Endocarditis: A Case Report and Statistical Analysis of the Literature.

Porter RS, Hay CM

Case reports in infectious diseases.. 2020 2020 :8890211. Epub 07/20/2020.

Safety and tolerability of HIV-1 multiantigen pDNA vaccine given with IL-12 plasmid DNA via electroporation, boosted with a recombinant vesicular stomatitis virus HIV Gag vaccine in healthy volunteers in a randomized, controlled clinical trial.

Elizaga ML, Li SS, Kochar NK, Wilson GJ, Allen MA, Tieu HVN, Frank I, Sobieszczyk ME, Cohen KW, Sanchez B, Latham TE, Clarke DK, Egan MA, Eldridge JH, Hannaman D, Xu R, Ota-Setlik A, McElrath MJ, Hay CM,

PloS one.. 2018 13 (9):e0202753. Epub 09/20/2018.

DNA Priming Increases Frequency of T-Cell Responses to a Vesicular Stomatitis Virus HIV Vaccine with Specific Enhancement of CD8 T-Cell Responses by Interleukin-12 Plasmid DNA.

Li SS, Kochar NK, Elizaga M, Hay CM, Wilson GJ, Cohen KW, De Rosa SC, Xu R, Ota-Setlik A, Morris D, Finak G, Allen M, Tieu HV, Frank I, Sobieszczyk ME, Hannaman D, Gottardo R, Gilbert PB, Tomaras GD, Corey L, Clarke DK, Egan MA, Eldridge JH, McElrath MJ, Frahm N,

Clinical and vaccine immunology : CVI.. 2017 November 24 (11)Epub 11/06/2017.

Stopping conventional showering decreases Pseudomonas infections in left ventricular assist device patients.

Aburjania N, Sherazi S, Tchantchaleishvili V, Alexis JD, Hay CM

The International journal of artificial organs.. 2017 June 940 (6):282-285. Epub 04/18/2017.

Immunogenicity of a novel Clade B HIV-1 vaccine combination: Results of phase 1 randomized placebo controlled trial of an HIV-1 GM-CSF-expressing DNA prime with a modified vaccinia Ankara vaccine boost in healthy HIV-1 uninfected adults.

Buchbinder SP, Grunenberg NA, Sanchez BJ, Seaton KE, Ferrari G, Moody MA, Frahm N, Montefiori DC, Hay CM, Goepfert PA, Baden LR, Robinson HL, Yu X, Gilbert PB, McElrath MJ, Huang Y, Tomaras GD,

PloS one.. 2017 12 (7):e0179597. Epub 07/20/2017.

A Randomized, Double-Blind, Placebo-Controlled Phase II Trial Investigating the Safety and Immunogenicity of Modified Vaccinia Ankara Smallpox Vaccine (MVA-BN®) in 56-80-Year-Old Subjects.

Greenberg RN, Hay CM, Stapleton JT, Marbury TC, Wagner E, Kreitmeir E, Röesch S, von Krempelhuber A, Young P, Nichols R, Meyer TP, Schmidt D, Weigl J, Virgin G, Arndtz-Wiedemann N, Chaplin P

PloS one.. 2016 11 (6):e0157335. Epub 06/21/2016.

Specificity and 6-month durability of immune responses induced by DNA and recombinant modified vaccinia Ankara vaccines expressing HIV-1 virus-like particles.

Goepfert PA, Elizaga ML, Seaton KE, Tomaras GD, Montefiori DC, Sato A, Hural J, Derosa SC, Kalams SA, McElrath MJ, Keefer MC, Baden LR, Lama JR, Sanchez J, Mulligan MJ, Buchbinder S, Hammer S, Koblin B, Pensiero M, Butler C, Moss B, Robinson HL, ,

The Journal of infectious diseases.. 2014 July 1210 (1):99-110. Epub 01/07/2014.

A phase I double blind, placebo-controlled, randomized study of a multigenic HIV-1 adenovirus subtype 35 vector vaccine in healthy uninfected adults.

Keefer MC, Gilmour J, Hayes P, Gill D, Kopycinski J, Cheeseman H, Cashin-Cox M, Naarding M, Clark L, Fernandez N, Bunce CA, Hay CM, Welsh S, Komaroff W, Hachaambwa L, Tarragona-Fiol T, Sayeed E, Zachariah D, Ackland J, Loughran K, Barin B, Cormier E, Cox JH, Fast P, Excler JL

PloS one.. 2012 7 (8):e41936. Epub 08/03/2012.

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial.

Treanor JJ, Schiff GM, Hayden FG, Brady RC, Hay CM, Meyer AL, Holden-Wiltse J, Liang H, Gilbert A, Cox M

JAMA.. 2007 April 11297 (14):1577-82. Epub 1900 01 01.

Dose-related safety and immunogenicity of a trivalent baculovirus-expressed influenza-virus hemagglutinin vaccine in elderly adults.

Treanor JJ, Schiff GM, Couch RB, Cate TR, Brady RC, Hay CM, Wolff M, She D, Cox MM

The Journal of infectious diseases.. 2006 May 1193 (9):1223-8. Epub 03/28/2006.

Combination therapy with polymyxin B for the treatment of multidrug-resistant Gram-negative respiratory tract infections.

Sobieszczyk ME, Furuya EY, Hay CM, Pancholi P, Della-Latta P, Hammer SM, Kubin CJ

The Journal of antimicrobial chemotherapy.. 2004 August 54 (2):566-9. Epub 07/21/2004.

Persistence of human immunodeficiency virus type 1-specific cytotoxic T-lymphocyte clones in a subject with rapid disease progression.

Islam SA, Hay CM, Hartman KE, He S, Shea AK, Trocha AK, Dynan MJ, Reshamwala N, Buchbinder SP, Basgoz NO, Kalams SA

Journal of virology.. 2001 May 75 (10):4907-11. Epub 1900 01 01.

Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection.

Hay CM, Ruhl DJ, Basgoz NO, Wilson CC, Billingsley JM, DePasquale MP, D'Aquila RT, Wolinsky SM, Crawford JM, Montefiori DC, Walker BD

Journal of virology.. 1999 July 73 (7):5509-19. Epub 1900 01 01.

Efficient processing of the immunodeficient HLA A-0201 restricted human immunodeficiency virus type 1 cytotoxic T lymphocyte Epitope despite multiple variations in the Epitope flanking sequences

Brander C, Young OO, Jones NG, Lee Y, Goulder P, Johnson RP, Trocha A, Colbert D, Hay CM, Buchbinder S, Bergman C, Zweerink H, Wolinsky S, Blattner Wam Kalams S, and Walker B.

Journal of Virology. 1999; 72: 10191-10198.

Ligand affinity of the 67-kD elastin/laminin binding protein is modulated by the protein's lectin domain: visualization of elastin/laminin-receptor complexes with gold-tagged ligands.

Mecham RP, Whitehouse L, Hay M, Hinek A, Sheetz MP

The Journal of cell biology.. 1991 April 113 (1):187-94. Epub 1900 01 01.

Books

Fitzpatrick's Dermatology in General Medicine (2007)

Chapter: Antiviral Drugs

Authors: Hay, CM Reichman, RC

Publisher: McGraw-Hill Professional 2007

Gender Specific Medicine (2004)

Chapter: Gender-Specific Issues in Non-HIV Viral Infections

Authors: Sobieszyzyk, M Hay, CM

Publisher: Elsevier 2004

Clinical Virology (2002)

Chapter: Antiviral Agents

Authors: Inouye RT Panther L Hay CM Hammer SM

Publisher: Churchill-Livingston 2002

Ratings & Comments

At URMC, we believe that patients should be empowered to make the right decisions regarding their personal healthcare. To do so, transparency is critical. URMC partners with Press Ganey, to survey our patients about all aspects of their care experience. We are now putting this pertinent information at your fingertips by displaying star ratings for our providers along with anonymous patient comments on our website. This will help you make better-informed choices about how and with whom you seek care. Click here to learn more about the surveys used to generate this vital information. Learn more about our survey process.